Latest Immunotherapy News

Hearts and Minds Investments (HM1) reported a stellar 25.5% pre-tax portfolio return for FY25, outperforming global benchmarks and announcing a raised fully franked dividend of 9.0 cents per share with plans for continued increases.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

Amplia Therapeutics reports encouraging interim results from its ACCENT trial, with its drug narmafotinib improving progression-free survival and response rates in advanced pancreatic cancer.

Immutep has received encouraging feedback from the FDA on its immunotherapy eftilagimod alfa combined with KEYTRUDA for patients with low PD-L1 expression in head and neck cancer, opening potential accelerated approval pathways.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.

Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.